Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate
Steffen Emmert, Holger A. Haenssle, John R. Zibert, et al.
PLoS ONE (2016) Vol. 11, Iss. 9, pp. e0160096-e0160096
Open Access | Times Cited: 20

Showing 20 citing articles:

Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly, Xavier Thuru, Bruno Quesnel
NAR Cancer (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 201
Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs
Christopher G. Parker, Christian A. Kuttruff, Andrea Galmozzi, et al.
ACS Central Science (2017) Vol. 3, Iss. 12, pp. 1276-1285
Open Access | Times Cited: 61
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?
Auriane de Pellegars-Malhortie, Laurence Picque Lasorsa, Thibault Mazard, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 949-949
Open Access | Times Cited: 5
Discovery of Small Molecules for the Reversal of T Cell Exhaustion
Brett S. Marro, Jaroslav Žák, Reza Beheshti Zavareh, et al.
Cell Reports (2019) Vol. 29, Iss. 10, pp. 3293-3302.e3
Open Access | Times Cited: 41
Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis
Katrin Singer, Katja Dettmer, Petra Unger, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 24
Sequential receptor–mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment
Jingmin Shen, Chao Sun, Zhicheng Wang, et al.
International Journal of Pharmaceutics (2021) Vol. 601, pp. 120553-120553
Closed Access | Times Cited: 18
Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate
Guochun Jiang, Emanual Maverakis, Michelle Cheng, et al.
JCI Insight (2019) Vol. 4, Iss. 7
Open Access | Times Cited: 22
Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis
Eggert Stockfleth, Mike Bastian
Expert Opinion on Drug Metabolism & Toxicology (2018) Vol. 14, Iss. 9, pp. 911-918
Closed Access | Times Cited: 11
Nanotechnology-mediated immunochemotherapy with Ingenol-3-Mebutate for Systematic Anti-tumor Effects
Mian Yu, Miaoqing Zhao, Rilei Yu, et al.
Journal of Controlled Release (2019) Vol. 304, pp. 242-258
Closed Access | Times Cited: 10
Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel
Sònia Segura, Alejandra Gadea, Lara Nonell, et al.
PLoS ONE (2020) Vol. 15, Iss. 5, pp. e0232146-e0232146
Open Access | Times Cited: 8
Ingenol mebutate induces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing
Stephan Alexander Braun, Julia A. Baran, Holger Schrumpf, et al.
European journal of medical research (2018) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis
Valeria Righi, Elisabetta Tarentini, Adele Mucci, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Fast Ablation of Anogenital Warts of the Urinary Meatus by Low-dose Ingenol Mebutate Gel
Stephan Alexander Braun, Martin Barsch, Peter Arne Gerber
Sexually Transmitted Diseases (2018) Vol. 45, Iss. 10, pp. e80-e82
Open Access | Times Cited: 6
Successful treatment of condylomata acuminata at the urethral meatus with high-dose ingenol mebutate gel: Report of two cases
Álvaro Martínez‐Doménech, Jorge Magdaleno‐Tapial, Marta García‐Legaz Martínez, et al.
International Journal of STD & AIDS (2019) Vol. 30, Iss. 8, pp. 817-819
Closed Access | Times Cited: 6
Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma
Ma Reyes García‐de‐la‐Fuente, Marı́a Santacana, Joan Verdaguer, et al.
Australasian Journal of Dermatology (2020) Vol. 61, Iss. 2
Closed Access | Times Cited: 5
A Case Series of Bowen’s Disease Treated with the Combination of Cryosurgery and Ingenol Mebutate and Followed Up with Optical Coherence Tomography
Georgios Gaitanis, Theodora Tsironi, Panagiota Spyridonos, et al.
Case Reports in Dermatological Medicine (2018) Vol. 2018, pp. 1-4
Open Access | Times Cited: 3
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts
Stephan A. Braun, Alexander T. Bauer, Csongor Németh, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13377-13377
Open Access | Times Cited: 2
Time‐lapse imaging points towards a non‐toxic, mainly immune‐driven mode of action of ingenol mebutate in the treatment of anogenital warts
Stephan A. Braun, Erich Bünemann, Julia A. Baran, et al.
Experimental Dermatology (2018) Vol. 27, Iss. 6, pp. 675-677
Closed Access | Times Cited: 1
Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp
Eggert Stockfleth, Catherine Α. Harwood, C. Serra‐Guillén, et al.
British Journal of Dermatology (2017) Vol. 178, Iss. 2, pp. 433-442
Closed Access
Page 1

Scroll to top